These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17671129)

  • 1. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; O'Brien S; Flinn IW; Kipps TJ; Weiss M; Rai K; Lin TS; Woodworth J; Wynne D; Reid J; Molina A; Leigh B; Harris S
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4448-55. PubMed ID: 17671129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
    Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
    Pathan NI; Chu P; Hariharan K; Cheney C; Molina A; Byrd J
    Blood; 2008 Feb; 111(3):1594-602. PubMed ID: 18032710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
    Flynn J; Jones J; Johnson AJ; Andritsos L; Maddocks K; Jaglowski S; Hessler J; Grever MR; Im E; Zhou H; Zhu Y; Zhang D; Small K; Bannerji R; Byrd JC
    Leukemia; 2015 Jul; 29(7):1524-9. PubMed ID: 25708835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
    Lin TS; Stock W; Xu H; Phelps MA; Lucas MS; Guster SK; Briggs BR; Cheney C; Porcu P; Flinn IW; Grever MR; Dalton JT; Byrd JC
    Leuk Lymphoma; 2009 Dec; 50(12):1958-63. PubMed ID: 19860603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
    J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
    Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
    J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
    J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.
    Schweighofer CD; Tuchscherer A; Sperka S; Meyer T; Rattel B; Stein S; Ismail S; Elter T; Staib P; Reiser M; Hallek M
    Cancer Immunol Immunother; 2012 Dec; 61(12):2367-73. PubMed ID: 23090290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
    Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
    Tong WG; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA; Mahadocon K; Chen T; Kegley P; Hoch U; Wierda WG
    J Clin Oncol; 2010 Jun; 28(18):3015-22. PubMed ID: 20479412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
    Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
    Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
    Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
    Gandhi V; Plunkett W; Bonate PL; Du M; Nowak B; Lerner S; Keating MJ
    Clin Cancer Res; 2006 Jul; 12(13):4011-7. PubMed ID: 16818700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.